β-Lactams and Ureas as Cross Inhibitors of Prokaryotic Systems

β-Lactams in the last thirty years have been viewed as universal acylating agents of serine and cysteine enzymes both prokaryotic eukaryotic systems. More recently, their use has propelled by COVID-19 pandemic, thus broadening application inhibitors viral enzymes. The urea-based drugs extensively studied aforementioned focus this review is decade’s drug discovery strategies, well new strategies that show utility expansion β-lactams ureas development antimicrobial antiviral drugs.